These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39075300)

  • 1. Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis.
    Dacoregio MI; Abrahão Reis PC; Gonçalves Celso DS; Romero LE; Altmayer S; Vilbert M; Moraes FY; Gomy I
    Eur Radiol; 2024 Jul; ():. PubMed ID: 39075300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
    Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.
    Paixão D; Guimarães MD; de Andrade KC; Nóbrega AF; Chojniak R; Achatz MI
    Cancer Imaging; 2018 Aug; 18(1):27. PubMed ID: 30107858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
    Dixon-Zegeye M; Shaw R; Collins L; Perez-Smith K; Ooms A; Qiao M; Pantziarka P; Izatt L; Tischkowitz M; Harrison RE; George A; Woodward ER; Lord S; Hawkes L; Evans DG; Franklin J; Hanson H; Blagden SP
    Trials; 2024 Feb; 25(1):103. PubMed ID: 38308321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review.
    Patel N; Felton K; Bhattacharya S; Almira-Suarez MI; Eze A; Turner J; Keating R; Oluigbo C; Schore RJ; Kilburn L; Packer RJ; Myseros JS; Bornhorst M
    J Neurosurg Pediatr; 2023 Mar; 31(3):258-267. PubMed ID: 36609372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
    Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
    Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management.
    Consul N; Amini B; Ibarra-Rovira JJ; Blair KJ; Moseley TW; Taher A; Shah KB; Elsayes KM
    AJR Am J Roentgenol; 2021 Jan; 216(1):252-263. PubMed ID: 33151095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
    Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between choroid plexus carcinoma and Li-Fraumeni syndrome: implications of TP53 mutations and management strategies-a case-based narrative review.
    Mallik D; Gopal S; Scalia G; Umana G; Rajeswarie RT; Chaurasia B
    Childs Nerv Syst; 2024 Jun; 40(6):1699-1705. PubMed ID: 38316675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body MRI Screening for Carriers of Germline TP53 Mutations-A Systematic Review and Meta-Analysis.
    Temperley HC; O'Sullivan NJ; Mac Curtain BM; Qian W; Temperley TS; Murray A; Corr A; Brennan I; Gallagher D; Meaney JF; Kelly ME
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.
    O'Neill AF; Voss SD; Jagannathan JP; Kamihara J; Nibecker C; Itriago-Araujo E; Masciari S; Parker E; Barreto M; London WB; Garber JE; Diller L
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29077256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of Intervention and Cancer Detection on Initial versus Subsequent Whole-body MRI Screening in Li-Fraumeni Syndrome.
    Kagami LAT; Du YK; Fernandes CJ; Le AN; Good M; Duvall MM; Baldino SE; Powers J; Zelley K; States LJ; Mathew MC; Katona BW; MacFarland SP; Maxwell KN
    Cancer Prev Res (Phila); 2023 Sep; 16(9):507-512. PubMed ID: 37428016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
    Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
    Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.